A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
- Conditions
- AmyloidosisSystemic Light Chain Amyloidosis
- Interventions
- Registration Number
- NCT01789242
- Lead Sponsor
- Criterium, Inc.
- Brief Summary
This is a dose finding study to evaluate the safety and determine the maximum tolerated dose of carfilzomib in patients with previously treated systemic light-chain amyloidosis.
- Detailed Description
This is a dose finding study to evaluate the safety and determine the maximum tolerated dose of carfilzomib in patients with previously treated systemic light-chain amyloidosis. The study will also explore the efficacy of carfilzomib in both proteasome inhibitor-naive and proteasome inhibitor-exposed patients including hematologic response, organ response, progression free survival, and time to next therapy.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 32
-
Males and females ≥ 18 years of age
-
Histologically-proven AL amyloidosis, confirmed by positive Congo red stain with green birefringence on polarized light microscopy with evidence of measurable clonal disease that requires active treatment as defined below:
-
Patients must have clonal disease measureable by serum free light chain (FreeliteTM) assay:
- For the dose-escalation cohort: this is defined as having any elevation in the amyloidogenic (i.e. clonal) light chain with an abnormal free kappa:lambda ratio
- For the dose expansion cohorts: in addition to the above, there must be a difference between the amyloidogenic (i.e. clonal) and non-amyloidogenic light chain (dFLC) of at least 50mg/L (5mg/dL)
-
Relapsed (progressed after prior response) or refractory (failed to achieve at least a partial response) to at least one prior therapy for amyloidosis.
- Patients that received an autologous stem cell transplant must be at least 3 months post-transplant and recovered from acute transplant-related toxicities.
- Patients that were unable to tolerate at least 1 cycle of an alkylating agent plus corticosteroid (e.g. melphalan + dexamethasone) or alternative prior regimen because of severe adverse events (e.g. hypersensitivity reaction) may be considered after discussion with the study PI/Medical Monitor.
-
Objective, measureable, symptomatic organ involvement, defined as one or more of the following:
- Kidney: albuminuria ≥ 500 mg/day in a 24-hour urine specimen
- Heart: presence of mean left ventricular wall thickness on echocardiogram greater than 12 mm in the absence of hypertension or valvular heart disease, or unexplained low voltage (< 0.5 mV) on ECG, or NT-proBNP > 332 ng/L in the absence of impaired renal function [estimated glomerular filtration rate (eGFR) < 45 mL/min]
- Liver: hepatomegaly on physical exam with elevated alkaline phosphatase > 1.5 x ULN
- GI Tract: biopsy showing amyloid deposition along with symptoms such as GI bleeding or persistent diarrhea (> 4 loose stools/day) Autonomic or Peripheral Nervous System: defined as orthostasis, symptoms of nausea or dysgeusia, recurrent diarrhea or constipation, abnormal sensory and/or motor findings on neurologic exam, or gastric atony by gastric emptying scan
- Note: Skin, lymph node, or soft tissue involvement; carpal tunnel syndrome; or bone marrow amyloid as the sole clinical manifestations of amyloidosis are not sufficient for inclusion.
-
Amyloid cardiac biomarker stage I or II disease Staging defined by NT-proBNP and troponin T cut-offs of < 332 pg/mL and <0.035 ng/mL, respectively, as thresholds: Stage I, both under threshold; and Stage II, either troponin or NT-proBNP (but not both) over threshold. If troponin T is not available at local institution, troponin I may be used, but threshold is <0.1 ng/mL.23
-
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
-
Clinical laboratory values as specified within 14 days of treatment:
- Absolute neutrophil count (ANC) ≥ 1.0 x 109/L
- Hemoglobin ≥8 g/dL [transfusion permitted]
- Platelet count ≥75.0 x 109/L
- Total bilirubin ≤ 2 x Upper Limit of Normal (ULN)
- Alkaline phosphatase ≤ 5 x ULN
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.5 x ULN
- CrCl ≥ 30 mL/min as measured by 24-hour urine
- Screening ANC should be independent of granulocyte-and granulocyte/macrophage colony stimulating factor (G-CSF and GM-CSF) support for at least 1 week and of pegylated G-CSF for at least 2 weeks
- Screening platelet count should be independent of platelet transfusions for at least 2 weeks
-
Written informed consent in accordance with federal, local, and institutional guidelines
-
Females of childbearing potential must agree to ongoing pregnancy testing and to practice contraception or abstain from heterosexual intercourse
-
Male patients must agree to practice contraception or to abstain from heterosexual intercourse
-
Male patients must agree not to donate semen or sperm
-
Life expectancy of ≥ 3 months
-
Pregnant or lactating females
-
Major surgery within 21 days prior to first dose
-
Acute active infection requiring systemic antibiotics, antivirals, or antifungals within 14 days prior to first dose
-
Treatment with an experimental drug within 28 days of first dose
-
Active Human Immunodeficiency Virus (HIV) or hepatitis B or C infection
-
Bone marrow plasma cells ≥ 30% or clinical manifestations of multiple myeloma, such as hypercalcemia or lytic bone lesions
-
Cardiac exclusions:
- Left ventricular ejection fraction (LVEF) < 40%
- Amyloid cardiac biomarker stage III disease, defined as both NT-proBNP ≥ 332 pg/mL and troponin T ≥ 0.035 ng/mL. If troponin T is not available at local institution, troponin I may be used, but cut-off is ≥ 0.1 ng/mL
- New York Heart Association (NYHA) classification III or IV heart failure (see Appendix G) despite medical management
- Unstable angina or myocardial infarction within 6 months prior to first dose
- Grade 2 or 3 atrioventricular (AV) block (Mobitz type I is permitted) or sick sinus syndrome, unless subject has a pacemaker
- Known history of sustained (> 30 second) ventricular tachycardia or cardiac syncope. Known history of recurrent non-sustained ventricular tachycardia (> 3 beats) despite anti-arrhythmic therapy
- Supine systolic blood pressure < 90 mm Hg, or symptomatic orthostatic hypotension, or a decrease in systolic blood pressure upon standing of > 20 mm Hg despite medical management (e.g. midodrine, fludrocortisones)
-
Significant peripheral neuropathy (Grade 3, Grade 4, or Grade 2 with pain) within 14 days prior to first dose
-
Severe diarrhea (≥ grade 3) not controllable with medication or that requires total parenteral nutrition
-
History of bleeding diathesis, known factor X deficiency (level < 20%), or requirement for therapeutic anticoagulation with warfarin
-
Known allergies to carfilzomib or Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)
-
Presence of other active malignancy with the exception of non-melanoma skin cancer, cervical cancer, treated early-stage prostate cancer provided that prostate-specific antigen is within normal limits, or any completely resected carcinoma in situ
-
Serious psychiatric or medical conditions that could interfere with treatment
-
Contraindication to any of the required concomitant drugs, including antiviral (e.g. Valacyclovir)
-
Patients in whom the required program of oral and IV fluid hydration is contraindicated, e.g. due to severe pre-existing pulmonary, cardiac, or renal impairment
-
Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to first dose.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Carfilzomib Carfilzomib All eligible subjects will receive the study intervention of Carfilzomib. Patients with suboptimal hematologic responses (\<VGPR after 4 cycles) will have Dexamethasone added to their treatment. Carfilzomib Dexamethasone All eligible subjects will receive the study intervention of Carfilzomib. Patients with suboptimal hematologic responses (\<VGPR after 4 cycles) will have Dexamethasone added to their treatment.
- Primary Outcome Measures
Name Time Method Adverse Events as a Measure of Safety and Tolerability Throughout treatment, estimated at 8 months per patient Review of adverse events for safety and to determine the maximum tolerated dose of the combination treatment
- Secondary Outcome Measures
Name Time Method Hematologic Response Every 28 days while on treatment (estimated at 8 months per patient) Hematologic Response Rates (PR, VGPR, and CR
Organ Response Every 112 days while on treatment (estimated at 8 months per patient) Organ response rates by standard criteria
Progression Free Survival throughout study and follow up (every 2-3 months for 2 years Time to next therapy throughout follow up (every 2-3 months for 2 years)
Trial Locations
- Locations (10)
Abramson Cancer Center at the University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
Winship Cancer Institute of Emory University
🇺🇸Atlanta, Georgia, United States
John Theurer Cancer Center at Hackensack University Medical Center
🇺🇸Hackensack, New Jersey, United States
Memorial Sloan-Kettering Cancer Center
🇺🇸New York, New York, United States
City of Hope
🇺🇸Duarte, California, United States
Stanford Cancer Institute
🇺🇸Stanford, California, United States
Boston University Medical Center
🇺🇸Boston, Massachusetts, United States
Columbia University
🇺🇸New York, New York, United States
Oregon Health and Sciences University
🇺🇸Portland, Oregon, United States
Duke University Medical Center
🇺🇸Durham, North Carolina, United States